Published online May 18, 2016. doi: 10.5312/wjo.v7.i5.272
Peer-review started: July 29, 2015
First decision: September 30, 2015
Revised: January 12, 2016
Accepted: March 7, 2016
Article in press: March 9, 2016
Published online: May 18, 2016
Processing time: 286 Days and 4.2 Hours
The debate on how best to manage patients with metal-on-metal (MOM) hip implants continues. With over 1 million patients affected worldwide, the impact is far reaching. The majority of the aggressive failures of MOM hip implants have been dealt with by revision hip surgery, leaving patients with a much more indolent pattern of failure of devices that have been in situ for more than 10 years. The longer-term outcome for such patients remains unknown, and much debate exists on how best to manage these patients. Regulatory guidance is available but remains open to interpretation due to the lack of current evidence and long-term studies. Metal ion thresholds for concern have been suggested at 7 ppb for hip resurfacing arthroplasty and below this level for large diameter total hip arthroplasties. Soft tissue changes including pseudotumours and muscle atrophy have been shown to progress, but this is not consistent. New advanced imaging techniques are helping to diagnose complications with metal hips and the reasons for failure, however these are not widely available. This has led to some centres to tackle difficult cases through multidisciplinary collaboration, for both surgical management decisions and also follow-up decisions. We summarise current evidence and consider who is at risk, when revision should be undertaken and how patients should be managed.
Core tip: Evidence supporting the management of metal on metal hips is lacking, and guidance is open to interpretation. Until supporting evidence is available, an evidence based multi-disciplinary approach on a case-by-case basis is considered a safe method to help surgeons make decisions and potentially improve patient outcomes.